Literature DB >> 23266743

Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study.

Emmanuel Barrat1, Yassine Zaïr, Pascal Sirvent, Patrice Chauveau, Corinne Maudet, Béatrice Housez, Elodie Derbord, Jean-François Lescuyer, Jean-Marie Bard, Murielle Cazaubiel, Sébastien L Peltier.   

Abstract

PURPOSE: To determine the effect of 4 weeks of supplementation, then, withdrawal of a dietary supplement (DS) containing red yeast rice extract, policosanol and artichoke leaf extract at twice the recommended daily dose (6 tablets, 6-TAB) compared to the usual dose (3-TAB) or to a placebo (PLA), on blood lipid profiles and safety biomarkers.
METHODS: Forty-five healthy subjects (15 per group), with untreated hypercholesterolaemia, were included in this randomised, double-blind, placebo-controlled clinical trial.
RESULTS: After 4 weeks of supplementation, LDL-C was significantly lower in 6-TAB (-0.21 g/l; 95 % CI -0.38 to -0.03 g/l; p = 0.0217) and 3-TAB (-0.25 g/l; 95 % CI -0.42 to -0.07 g/l; p = 0.0071) compared to PLA, although no difference in LDL-cholesterol was observed between the two groups, while no effect was seen on triacylglycerol and HDL-cholesterol. Four weeks after the end of supplementation, no difference in LDL-C was seen between the PLA group and the DS-treated groups. The muscle breakdown biomarkers, as well as biomarkers of liver and renal function, were altered by neither dose of the DS. Acute application of the DS on permeabilised skeletal muscle fibres of rats did not induce deleterious effects on mitochondrial function.
CONCLUSIONS: Supplementation with twice the recommended dose of the DS was effective in reducing LDL-cholesterol and appeared safe, but according to the present results, no additional benefit could be achieved compared to the recommended dose.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23266743     DOI: 10.1007/s00394-012-0486-2

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  29 in total

1.  Dose response, safety, and efficacy of an extended-release formulation of lovastatin in adults with hypercholesterolemia.

Authors:  John R Crouse; Peter Lukacsko; Robert Niecestro; Lawrence Friedhoff
Journal:  Am J Cardiol       Date:  2002-01-15       Impact factor: 2.778

Review 2.  Statin-induced myopathies.

Authors:  Michał Tomaszewski; Karolina M Stępień; Joanna Tomaszewska; Stanisław J Czuczwar
Journal:  Pharmacol Rep       Date:  2011       Impact factor: 3.024

3.  Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins.

Authors:  P Sirvent; O Fabre; S Bordenave; D Hillaire-Buys; E Raynaud De Mauverger; A Lacampagne; J Mercier
Journal:  Toxicol Appl Pharmacol       Date:  2012-01-17       Impact factor: 4.219

4.  [Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].

Authors:  Fang-yong Jiang; Li-ping Sun; Jin Yang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2011-12

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Simvastatin induces impairment in skeletal muscle while heart is protected.

Authors:  Pascal Sirvent; Sylvain Bordenave; Marianne Vermaelen; Belle Roels; Guy Vassort; Jacques Mercier; Eric Raynaud; Alain Lacampagne
Journal:  Biochem Biophys Res Commun       Date:  2005-10-26       Impact factor: 3.575

7.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

8.  Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.

Authors:  Heiner K Berthold; Susanne Unverdorben; Ralf Degenhardt; Michael Bulitta; Ioanna Gouni-Berthold
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

9.  Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia.

Authors:  Matthew Klimek; Shan Wang; Adeleye Ogunkanmi
Journal:  P T       Date:  2009-06

10.  Comparison of the efficacy, safety and tolerability of original policosanol versus other mixtures of higher aliphatic primary alcohols in patients with type II hypercholesterolemia.

Authors:  G Castaño; L Fernández; R Mas; J Illnait; J Fernández; M Mesa; E Alvarez; M Lezcay
Journal:  Int J Clin Pharmacol Res       Date:  2002
View more
  9 in total

1.  Effects of long-term supplementation of policosanol on blood cholesterol/glucose levels and 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in a rat model fed high cholesterol diets.

Authors:  Jung-Yun Lee; Hwang-Yong Choi; Yu-Ri Kang; Hung-Bae Chang; Hyoung-Sik Chun; Mee-Sook Lee; Young-In Kwon
Journal:  Food Sci Biotechnol       Date:  2016-06-30       Impact factor: 2.391

2.  Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

Authors:  Arrigo F G Cicero; Alessandro Colletti; Gani Bajraktari; Olivier Descamps; Dragan M Djuric; Marat Ezhov; Zlatko Fras; Niki Katsiki; Michel Langlois; Gustavs Latkovskis; Demosthenes B Panagiotakos; Gyorgy Paragh; Dimitri P Mikhailidis; Olena Mitchenko; Bernhard Paulweber; Daniel Pella; Christos Pitsavos; Željko Reiner; Kausik K Ray; Manfredi Rizzo; Amirhossein Sahebkar; Maria-Corina Serban; Laurence S Sperling; Peter P Toth; Dragos Vinereanu; Michal Vrablík; Nathan D Wong; Maciej Banach
Journal:  Arch Med Sci       Date:  2017-08-04       Impact factor: 3.318

Review 3.  Red Yeast Rice for Hypercholesterolemia.

Authors:  Arrigo F G Cicero; Federica Fogacci; Maciej Banach
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Jul-Sep

4.  Effects of a Dietary Supplement with Barley Sprout Extract on Blood Cholesterol Metabolism.

Authors:  A Ri Byun; Hyejin Chun; Jin Lee; Sang Wha Lee; Hong Soo Lee; Kyung Won Shim
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-25       Impact factor: 2.629

5.  Diet and Nutraceutical Supplementation in Dyslipidemic Patients: First Results of an Italian Single Center Real-World Retrospective Analysis.

Authors:  Andrea Pasta; Elena Formisano; Anna Laura Cremonini; Elio Maganza; Erika Parodi; Sabrina Piras; Livia Pisciotta
Journal:  Nutrients       Date:  2020-07-10       Impact factor: 5.717

Review 6.  Bioactive Compounds from Cardoon as Health Promoters in Metabolic Disorders.

Authors:  Luís R Silva; Telma A Jacinto; Paula Coutinho
Journal:  Foods       Date:  2022-01-25

7.  A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia.

Authors:  Yinhua Li; Long Jiang; Zhangrong Jia; Wei Xin; Shiwei Yang; Qiu Yang; Luya Wang
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

8.  Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial.

Authors:  Arrigo Francesco Giuseppe Cicero; Alessandro Colletti; Federica Fogacci; Marilisa Bove; Martina Rosticci; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-06-23

Review 9.  Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?

Authors:  Arrigo F G Cicero; Federica Fogacci; Anca Pantea Stoian; Michal Vrablik; Khalid Al Rasadi; Maciej Banach; Peter P Toth; Manfredi Rizzo
Journal:  Curr Atheroscler Rep       Date:  2021-08-04       Impact factor: 5.113

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.